- Home
- CANF vs DRCT Comparison
CANF vs DRCT Comparison
Compare CANF & DRCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CANF
- DRCT
- Stock Information
- Founded
- CANF 1994
- DRCT 2018
- Country
- CANF Israel
- DRCT United States
- Employees
- CANF N/A
- DRCT N/A
- Industry
- CANF Biotechnology: Pharmaceutical Preparations
- DRCT Computer Software: Programming Data Processing
- Sector
- CANF Health Care
- DRCT Technology
- Exchange
- CANF Nasdaq
- DRCT Nasdaq
- Market Cap
- CANF 14.8M
- DRCT 16.7M
- IPO Year
- CANF N/A
- DRCT 2022
- Fundamental
- Price
- CANF $1.04
- DRCT $0.54
- Analyst Decision
- CANF Strong Buy
- DRCT Strong Buy
- Analyst Count
- CANF 2
- DRCT 1
- Target Price
- CANF $14.00
- DRCT $6.00
- AVG Volume (30 Days)
- CANF 172.6K
- DRCT 3.0M
- Earning Date
- CANF 05-27-2025
- DRCT 05-06-2025
- Dividend Yield
- CANF N/A
- DRCT N/A
- EPS Growth
- CANF N/A
- DRCT N/A
- EPS
- CANF N/A
- DRCT N/A
- Revenue
- CANF $674,000.00
- DRCT $48,170,000.00
- Revenue This Year
- CANF $461.72
- DRCT $53.01
- Revenue Next Year
- CANF N/A
- DRCT $11.11
- P/E Ratio
- CANF N/A
- DRCT N/A
- Revenue Growth
- CANF N/A
- DRCT N/A
- 52 Week Low
- CANF $1.02
- DRCT $0.44
- 52 Week High
- CANF $4.69
- DRCT $6.59
- Technical
- Relative Strength Index (RSI)
- CANF 37.30
- DRCT 43.35
- Support Level
- CANF $0.98
- DRCT $0.54
- Resistance Level
- CANF $1.14
- DRCT $0.69
- Average True Range (ATR)
- CANF 0.06
- DRCT 0.13
- MACD
- CANF 0.01
- DRCT -0.02
- Stochastic Oscillator
- CANF 32.59
- DRCT 5.78
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).
About DRCT Direct Digital Holdings Inc.
Direct Digital Holdings Inc is an end-to-end, full-service programmatic advertising platform primarily focused on providing advertising technology, data-driven campaign optimization, and other solutions to underserved and less efficient markets on both the buy-side and sell-side of the digital advertising ecosystem. The company operates two reportable segments: sell-side advertising, which includes the results of Colossus Media, and buy-side advertising, which includes the results of Orange 142 and Huddled Masses. All of the company's revenues are attributed to the United States.